#India #Intas Pharmaceuticals #Ahmedabad #Prothya Biosolutions #Accord Plasma

Intas Pharmaceuticals Expands Global Presence by Acquiring Prothya Biosolutions

In a significant strategic move, Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has confirmed its agreement to acquire Prothya Biosolutions Belgium BV, along with all its subsidiaries. Prothya is recognized as a leader in the production of plasma-derived medicinal products (PDMP), primarily operating out of Belgium and the Netherlands. This acquisition is expected to close soon, pending the usual conditions, including regulatory approvals.

The acquisition represents a crucial step for Intas and Accord in their quest to enhance their presence in the PDMP market globally, extending their established leadership in India to a more expansive reach.

Founded in 2021, Prothya Biosolutions was formed from the amalgamation of Plasma Industries Belgium and Sanquin Plasma Products, bringing over 60 years of combined experience in plasma collection and PDMP development. With approximately 1,200 employees, Prothya operates collection centers across Hungary and has established itself as one of Europe’s largest plasma fractionators.

Binish Chudgar, the President of Intas and Accord, expressed his enthusiasm regarding the acquisition. He stated, “We are pleased to expand our plasma business by acquiring Prothya Biosolutions. This, combined with our fractionation capacity in India, positions us to create a truly global plasma platform that serves patients worldwide with critical therapies, often underprescribed.”

Intas has been actively supplying PDMP to hospitals since 2015, showcasing a robust annual fractionation capacity exceeding one million liters, with exports to various international markets. The company's operations in Gujarat are also set to expand, enhancing their ability to meet rising global demands.

Nir Epstein, CEO of Prothya, highlighted the company’s recent growth and market expansions, thanking the dedicated team for their unwavering commitment to patients. He emphasized the synergy with Accord, noting that they are poised to support Prothya in its next growth phase and global expansion.

The global PDMP market, particularly for Intravenous Immunoglobulin (IVIG), is currently valued at $30 billion, with projections suggesting it could reach $50 billion by 2035. The acquisition will grant Intas access to additional significant fractionation capacity, bolstered by Accord’s established commercial presence in 85 countries.

BofA Securities is advising Accord as the exclusive financial advisor in this transaction, while Evercore serves as the exclusive financial advisor to Prothya.

About Intas Pharmaceuticals

Intas Pharmaceuticals Ltd. is a vertically integrated pharmaceutical leader based in Ahmedabad, India. The company excels in formulation development, manufacturing, and marketing while also maintaining a backward integration of active pharmaceutical ingredients (API). Intas also has a strong biosimilars development and marketing capability, boasting over 15 products in the market.

The firm is committed to broadening global healthcare access by providing high-quality, affordable medications through strategic partnerships and significant investments in R&D to meet diverse health system needs worldwide. Under the brand of Accord Healthcare, Intas operates across 85 countries, establishing a solid infrastructure for sales, marketing, and distribution in major markets such as North America, Europe, and Asia-Pacific.

With a history steeped in both organic growth and acquisitions, Intas continues to enhance its portfolio and operational capacity year after year, bolstering its status as a prominent global player in the pharmaceutical arena.